PharmacoEconomics

, Volume 9, Issue 2, pp 101–105 | Cite as

The 4S Study and its Pharmacoeconomic Implications

  • John P. D. Reckless
Current Opinion

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Reckless JPD. Cost implications of lipid lowering treatments. PharmacoEconomics 1994; 6: 310–23PubMedGoogle Scholar
  2. 2.
    Davey-Smith G, Pekkanen J. Should there be a moratorium on cholesterol lowering drugs? BMJ 1992; 304: 431–4PubMedCrossRefGoogle Scholar
  3. 3.
    Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994; 308: 367–73PubMedCrossRefGoogle Scholar
  4. 4.
    Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results I and II. JAMA 1984; 251: 351–74CrossRefGoogle Scholar
  5. 5.
    Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle aged men with dyslipidemia. N Engl J Med 1987; 317: 1237–45PubMedCrossRefGoogle Scholar
  6. 6.
    Wysowski DK, Gross TP. Deaths due to accidents and violence in two recent trials of cholesterol-lowering drugs. Arch Intern Med 1990; 150: 2169–72PubMedCrossRefGoogle Scholar
  7. 7.
    Law MR, Wald NJ, Thompson SG. Assessing possible hazards of reducing serum cholesterol. BMJ 1994; 308: 373–9PubMedCrossRefGoogle Scholar
  8. 8.
    Scandinavian Simvastatin Survival Study. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9Google Scholar
  9. 9.
    Goldman L, Weinstein MC, Goldman PA, et al. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 1991; 265: 1145–51PubMedCrossRefGoogle Scholar
  10. 10.
    Martens LL, Rutten FFH, Erkelens DW, et al. Cost effectiveness of cholesterol-lowering therapy in the Netherlands: simvastatin versus cholestyramine. Am J Med 1989; 87 Suppl. 4A: 54S–8SPubMedCrossRefGoogle Scholar
  11. 11.
    Martens LL, Rutten FFH, Erkelens DW, et al. Clinical benefits and cost effectiveness of lowering serum cholesterol levels: the case of simvastatin and cholestyramine in the Netherlands. Am J Cardiol 1990; 65: 27F–32FPubMedCrossRefGoogle Scholar
  12. 12.
    Thorvik E, Aursnes I, Forsen L, et al. Costs and effects on longevity of lipid lowering drugs. Oslo: Unit for Health Services Research, National Institute of Public Health, 1993: Research Rep. No. F-1-1993Google Scholar
  13. 13.
    Jönsson B. Cost effectiveness: results from the Scandinavian Simvastatin Survival Study [abstract]. European Atherosclerosis Society 64th Congress Satellite Meeting. The clinical benefits of treating atherosclerosis: 1995 Jun 10–13; UtrechtGoogle Scholar
  14. 14.
    Simvastatin cost-effective in secondary prevention. Scrip 1995; 2013: 30Google Scholar
  15. 15.
    Reckless JPD. The economics of cholesterol lowering. Baillieres Clin Endocrinol Metab 1990; 4: 947–72PubMedCrossRefGoogle Scholar
  16. 16.
    Standing Medical Advisory Committee. Blood cholesterol testing and the cost-effectiveness of opportunistic cholesterol testing. Report to the Secretary of State for Health. London: Department of Health, 1990Google Scholar
  17. 17.
    Forrest P. Breast cancer screening: report to the Health Ministers of England, Wales, Scotland and Northern Ireland. London: Her Majesty’s Stationery Office, 1986: 1–102Google Scholar
  18. 18.
    Pitt B, Ellis SG, Mancini GBJ, et al. Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I). Am J Cardiol 1993; 72: 31–5PubMedCrossRefGoogle Scholar
  19. 19.
    Crouse III JR, Byington RP, Bond MG, et al. Pravastatin, lipids and atherosclerosis in the carotid arteries (PLAC-II) [published erratum appears in Am J Cardiol 1995; 75: 862]. Am J Cardiol 1995; 75: 455–9PubMedCrossRefGoogle Scholar
  20. 20.
    Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1289–98PubMedCrossRefGoogle Scholar
  21. 21.
    Watts GF, Lewis B, Brunt JNH, et al. Effects of coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas’ Atherosclerosis Regression Study (STARS). Lancet 1992; 339: 563–9PubMedCrossRefGoogle Scholar
  22. 22.
    West of Scotland Coronary Prevention Study Group. Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. Am J Cardiol 1995; 76: 485–91CrossRefGoogle Scholar
  23. 23.
    Reckless JPD. Cost effectiveness of lipid lowering drugs. Postgrad Med J 1993; 69 Suppl. 1: S30–3PubMedGoogle Scholar
  24. 24.
    Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333(20): 1301–7PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  • John P. D. Reckless
    • 1
  1. 1.School of Postgraduate MedicineUniversity of Bath, and Royal United HospitalBathEngland

Personalised recommendations